Drug/code
Registration
indication
Pre-IND
IND
|period
||period
|||period
Follow-up plan
DH001
Class 1 Chemical Drug
Phase II Study 2023
MY006
Class 1 Chemical Drug
Clinical Application in 2024
MY001
Class 3.1 Traditional Chinese Medicine
Ancient Classic Formula, Clinical Trial Exempt, Application for Market Approval in 2025
Raw white oral liquid
Improved New Drug
In 2025, Phase III Clinical Trial
Polyporus polysaccharide capsules
Improved New Drug
In 2026, Phase III Clinical Trial
MY007
Chinese Medicine Class 1.1
Clinical Approval Obtained in 2025
Asparagus Capsules
Improved New Drug
Oral Mucositis
Service hotline
Address：3 Fuyao Yi Lu, Doudao District, Jingmen City, Hubei Province, China
Transmissionh：0724-8686500
Email：hbmy_monyan@163.com
COPYRIGHT© 2022 Hubei Mengyang Pharmaceutical Co., LTD. All Rights Reserved E ICP 11014915; Internet Drug Information Service Certificate No. : (E) - Non-business -2016-0032
Technical Support: SUMA